Various embodiments disclosed relate to drug-coated balloon catheters for treating strictures in body lumens and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent.

Various embodiments disclosed relate to drug-coated balloon catheters for treating strictures in body lumens and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent.

A method of transarterial embolization agent delivery at a low pressure is provided. The method comprises advancing a delivery device with an occlusion structure in a retracted non-occlusive configuration through a supply artery to a vascular position in the supply artery that is in the vicinity of a target anatomical structure, the target structure having terminal capillary beds, expanding the occlusion structure from the retracted non-occlusive configuration to an expanded occlusive configuration, lowering a mean arterial pressure in a vascular space distal to the expanded occlusion structure, redirecting fluid flow from the collateral vessels toward the lowered pressure vascular space and into the target anatomical structure, injecting an embolization agent through the delivery device and into the lowered pressure vascular space, and delivering the embolization agent from the lowered pressure vascular space into the target anatomical structure. Other catheter assemblies and methods of use are also disclosed.

The invention provides a novel prostate dilation catheter, which comprises a main tube, wherein a urinary catheterization cavity, an internal capsule cavity, an external capsule cavity and a flushing cavity are provided inside the main tube, a composite bar-like high pressure water capsule is arranged in front portions of an outlet of the urinary catheterization cavity and an outlet of the flushing cavity, the composite bar-like high pressure water capsule comprises an internal capsule and an external capsule, the internal capsule is arranged inside the outer capsule and at a front end of the outer capsule, and the front ends of the internal capsule cavity and the external capsule cavity are formed with openings which are located inside the internal capsule and the external capsule respectively. Utilization of such structure makes the catheter will automatically move towards the inside of bladder after a bladder neck is dilated, so as to remove compression on an external sphincter to prevent occurrence of urinary incontinence; and in addition, it is more conducive to preoperative localization and postoperative fixation of the catheter, and can avoid bladder spasm caused by postoperative compression of the catheter on crypt.

A system and associated method for manipulating tissues and anatomical or other structures in medical applications for the purpose of treating diseases or disorders or other purposes. In one aspect, the system includes an expandable structure for enhancing engagement with median lobe prostate tissue.

A catheter treatment apparatus comprises an elongate tubular member and an expandable support. The expandable support comprises a radioactive substance to treat cancerous tissue and is configured to expand from a narrow profile for insertion to a wide profile to engage and treat tissue remaining after resection. The expandable support can be sized to fit within a volume of removed tissue to place the radioactive substance in proximity to the capsule and remaining tissue, to spare the capsule and proximate nerves and vessels to treat tissue in proximity to the capsule. The elongate tubular member may comprise a channel such as a lumen to pass a bodily fluid such as urine when the expandable support engages the tissue to treat the patient for a plurality of days. The treatment apparatus can be used to resect and diagnose tissue concurrently. Based on the diagnosis, targeted segmental treatment may be given.

The present invention describes a method for performing a prostate surgical treatment, said method comprising: arranging a catheter 1 inside of a urethra of a patient and anchored against the bladder neck of the patient subsequent to the filling of the balloon stopper unit 5 with a fluid when the balloon stopper unit 5 is arranged inside of the bladder of a patient;
said method also comprising injecting at least one anesthetic agent and adrenaline or injecting botulinum toxin (Botox) and/or penicillin to the prostate via the injection tube 9 and the hollow tip 10 at an intended position of the prostate.

Moreover, the present invention also refers to a kit comprising a catheter 1 according to the present invention and one or more syringe(s) 1000 containing adrenaline and at least one anesthetic agent and/or at least a syringe 1000 or vial containing botulinum toxin (Botox) and/or penicillin.

A method and device for facilitating the anastomotic healing of a patient after a radical prostatectomy surgical procedure, without a urethral catheter, comprising the steps of performing a radical prostatectomy, fixedly positioning a splinting element between the urethra and the bladder, across the urethral opening, placing the splinting element during the performing of the radical prostatectomy and prior to surgical closure. The fixed positioning is effected from a position within the bladder with anchoring the splinting element in position relative to the interior of the bladder, setting a separate urine drainage tube, and removing the splinting element, after anastomotic healing, with a retrieval element on the splinting element or with dissolving of the splinting element.

Provided herein are drug implants comprising a therapeutically active agent for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and a therapeutically active agent disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may comprise bicalutamide, e.g., for use in the treatment of prostate cancer.

A system and method for prostate cancer treatment under local anesthesia includes creating a superficial skin and subcutaneous block in a perineal area of a patient by administering a first anesthetizing agent; creating a deep nerve block under ultrasound guidance by administering a second anesthetizing agent, the second anesthetizing agent infiltrating cavernosal nerve bundle tissue and periprostatic space; and ablating prostate tissue. The office-based method, statistical models and computer generated treatment plans identify and ablate prostate tissue containing cancer through or via the perineum while preserving prostate function, and critical anatomical structures. Multiple technologies are integrated and processed to deliver a safe treatment procedure, under local anesthesia by integrating the information of magnetic resonance imaging and planning the ablative treatment using algorithms that ensure maximal precision in both killing cancerous tissue and preserving healthy tissue along with its corresponding function.